Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

The manuscript addresses the 3D chromatin architecture in monocytes from patients with alcohol-associated hepatitis and its relationship to enhanced transcription of innate immune genes. While the ...

HK) ("Akeso" or the "Company") is pleased to announce the acceptance of its Investigational New Drug (IND) application by the China National Medical Products Administration (NMPA) for AK139, a ...

Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Reports Q4 revenue $56.2M, consensus $52.25M. “Strong revenue growth for Fanapt is putting us on a significant growth trajectory for 2025 and ...

Vanda Pharmaceuticals Inc (VNDA) reports strong Fanapt sales growth and strategic initiatives, despite facing increased ...

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Wednesday,RTT News reports. They presently have a ...

The spot “is a clear violation” of the FDCA, “which requires that advertising for prescription drugs — including compounded ...

KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the 'NMPA') of China has recently approved the supplemental New Drug Application (the 'sNDA') of ...

Despite the failure of an eczema trial in December, Q32 Bio is sticking with bempikibart. But a phase 2-stage complement inhibitor and a number of the biotech’s “valued colleagues” won’t be so lucky.

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the company, Marketbeat reports. Two ...

Using the BiovitalsHF software to personalize recommendations got more patients on all four pillars of therapy.